Comment	Guideline	
Number	Document	Comments
1 (0.222.002	Paragraph (¶)	~ ~ · · · · · · · · · · · · · · · · · ·
1	3	Minor suggested edits.
2	4 and 5	The statement that has been made during the expert consultation of this draft guideline that there are actually no false negatives if one also considers all available reference data (including human data) is not necessarily supported by the available date. It has been asserted that the false negative substances (when compared to rabbit skin test data) are non-irritants in humans. However, it should be noted that each of these substances actually produced irritation in at least 20% (6/29 or 6/30) of the human volunteers. Jirova et al. (2007) concluded that these substances do not pose "significant acute skin irritation potential" because each substance produced irritation in fewer individuals than did the positive control substance, 20% sodium dodecyl sulfate (SDS, also SLS). However, di-n-propyl disulfide had 6/30 positive reactions (22/30 with SLS) and 2-isopropyl-2-isobutyl-1,3-dimethoxypropane had 6/29 positive reactions (26/29 with SLS). Furthermore, 2/6 individuals with positive reactions to di-n-propyl disulfide had a severity score of 2, indicating a moderate reaction, and one of these individuals had moderate scabbing at the application site (Kandarova, personal communication), indicative of a potential corrosive effect. The relative importance of human and animal data should be carefully considered, as summarized in the OSHA Hazard Communication Standard, which states that: "positive results from well-conducted animal studies are not necessarily negated by the lack of positive human experience but require an assessment of the robustness, quality and statistical power of both human and animal data." (see Federal Register Vol. 74, No. 188, section A.O.3.3, page 50443). Additionally, according to the available rabbit skin test data and using in vivo scores ≥2.3 as the threshold for an irritant response (i.e., as per the GHS), 13 irritant compounds were included in the SIVS validation database. Of these, 2 compounds, di-n-propyl disulfide and 2-isopropyl-2-isobutyl-1,3-dimethoxypropane, were false neg

Comment Number	Guideline Document Paragraph (¶)	Comments
	Taragraph (1)	and 5 of the TG, which are included in the Attached Tracked Document .
3	7	A continued concern from the USA is the possibility that the 12-21% false negatives generated by in vitro corrosivity test methods (15 different substances were identified by one or more of the in vitro corrosivity test methods as noncorrosive in one or more tests during the validation studies) may not be detected in the in vitro irritation test methods (i.e., resulting in a corrosive substance being unlabelled for dermal hazard). While one might conclude that using the sequential decision strategy set forth in OECD TG404, (e.g., QSAR, measuring pH, etc.) might correct these results, (e.g., any chemical with a pH extreme is considered a corrosive), it is unlikely that this could completely resolve this problem. For example, the identity of the substance being tested may be unknown such that QSAR analyses are not feasible. Additionally, many corrosives with a pH extreme are not corrosive, and routine use of such a classification criterion to eliminate false negative corrosives would therefore not likely be acceptable to industry, considering the increased cost of packaging and transport for substances erroneously labeled as corrosives. Furthermore, many corrosive substances do not have a pH in these extreme ranges, and this criterion still might not avoid false negatives. It should also be emphasized that there should be standardized methods provided for proper measurement of pH and associated buffering capacities. NICEATM is in the process of completing a study to evaluate these false negative substances, with results expected by May 2010. Due to the uncertain ability of the in vitro skin irritation test methods to identify false negative in vivo corrosives, additional text has been recommended for inclusion in paragraph 7 in order to identify the potential shortcoming of a purely in vitro testing strategy (i.e., when the only available information is derived from the in vitro corrosivity and irritation test methods) (see Attached Tracked Document).
4	7	Because of the potential limitations of these test method, it is unlikely that they could be considered as complete replacements for skin corrosivity and irritation testing as outlined in TG 404. Therefore, it is important that this point be recognized in the test guideline.

Guideline	
Document	Comments
Paragraph (¶)	
8 and 9	As currently written, paragraph 8 currently implies that solids, liquids, semi-solids and waxes were all represented in the validation study. However, among the referenced validation documents, 15 of the 58 chemicals of the Skin Irritation Validation Study are indicated as solids, and 43 are listed as liquids. None are indicated as "semi-solids" or "waxes". Of the 15 reported solids from the SIVS, NICEATM found a description of physical form for 6 chemicals that confirmed they are powder or crystalline solids, leaving 9 chemicals in question. Waxes are insoluble in water and using the compilation of physical chemical properties supplied by ECVAM for the SIVS chemicals, 7 of the remaining solids are identified as soluble in water; the final two solids reportedly have very low water solubility. For 2-ethylhexyl 4-aminobenzoate, NICEATM identified documentation from BASF on the preparation of an aqueous solution. The final solid, [(ethyl cis-4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazine-1-carboxylate) CAS 67914-69-6], is related to ketoconazole, a white powder, and differs by a methoxy group substituted for the methyl group at the pyridine ring. This information suggests that among the reported solids of the SIVS, there are no waxes. Therefore, we have proposed alternative wording (see paragraphs 8 and 9 in Attached Tracked Document) that delineates the types of substances included in the validation study from other testing that may have occurred independent of the validation study.
22	Minor suggested edits.
	Document Paragraph (¶)